Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Life, Journal Year: 2024, Volume and Issue: 14(4), P. 473 - 473

Published: April 4, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is not only related to traditional cardiovascular risk factors like type 2 diabetes mellitus and obesity, but it also an independent factor for the development of disease. MASLD has been shown be independently endothelial dysfunction atherosclerosis. characterized by a chronic proinflammatory response that, in turn, may induce prothrombotic state. Several mechanisms such as platelet dysfunction, changes coagulative factors, lower fibrinolytic activity can contribute Platelets are players addresses metabolic dysregulation; obesity insulin resistance hyperactivation. Furthermore, platelets exert direct effect on cells, particularly through release mediators from granules. Growing data literature support use antiplatelet agent treatment MASLD. The antiplatelets drugs seems beneficial effects hepatocellular carcinoma prevention patients with MASLD, since fibrosis progression cancer development. This review aims summarize main role pathogenesis its complications events fibrosis. we will examine therapy possible anti-fibrotic anti-tumor agent.

Language: Английский

---

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 20, 2024

Summary Background The new nomenclature of metabolic dysfunction‐associated steatotic liver disease (MASLD) substituting nonalcoholic fatty was proposed along with a category MASLD increased alcohol intake (MetALD). Aims We aimed to explore the cancer risk by and MetALD. Methods This nationwide cohort study included 3,596,709 participants who underwent health check‐up in 2011 South Korea. Steatotic (SLD) defined as index ≥30. Participants were categorized into four exclusive groups: MASLD, MetALD, other combination aetiology no SLD. subdistribution hazard ratio (SHR) calculated using Fine–Gray model after adjusting variables. Results During 33.9 million person‐years follow‐up, 285,845 (7.9%) developed cancers. Compared SLD, MetALD had an all cancer. Liver escalated from SLD (SHR, 1.16; 95% CI, 1.12–1.21), 2.06; 1.92–2.20) 8.16; 7.69–8.67). Gastrointestinal cancers including oesophagus, stomach, colorectal, biliary pancreas 1.13; 1.11–1.15), 1.17; 1.14–1.21) 1.09; 1.05–1.13). A modest increase lung hormone‐sensitive observed MASLD. Conclusions showed that are associated cancer, particularly gastrointestinal findings build evidence for clinical outcomes while highlighting importance managing properly

Language: Английский

---

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(4), P. e0299507 - e0299507

Published: April 16, 2024

Background and aims Metabolic dysfunction associated steatotic liver disease (MASLD) increases the risk of incident chronic kidney (CKD). However, relative CKD with increasing hepatic fibrosis, consequent mortality risk, remains underexplored in real-world cohorts. In this study, we sought to establish whether fibrosis is increased explore differences a cohort people living MASLD, contingent on status. Methods This was an observational study who underwent routine function testing Tayside, Scotland. MASLD defined as: elevated ALT (>30 U/L) or GGT (>73 U/L); presence diabetes, and/or hypertension, obesity; weekly alcohol consumption <14 units (112g (+/-8g) alcohol); negative screen for other aetiologies. Data collected from digital health records. We used log-binomial models quantify among those without Cox regression estimate dependent CKD. Results our (n = 2,046), 1,448 (70.8%) had 598 (29.2%) fibrosis; 161 (11.1%) 117 (19.6%) respectively also After excluding individuals structural, autoimmune, malignant 22), 593; 18.9% CKD) ( RR 1.31, 1.04–1.64, p 0.021). Increased observed HR 2.30, 1.49–3.56, <0.001) higher again both 5.07, 3.07–8.39, <0.014). Conclusions Liver independent factor MASLD. Furthermore, further co-morbid Given CKD, renal screening should be considered within surveillance programmes guidelines.

Language: Английский

---

Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism

Advanced Science, Journal Year: 2024, Volume and Issue: 11(31)

Published: June 18, 2024

Abstract Non‐alcoholic fatty liver disease (NAFLD) is a prominent cause of various chronic metabolic hepatic diseases with limited therapeutics. Rubicon, an essential regulator in lysosomal degradation, reported to exacerbate steatosis NAFLD mice and patients, indicating its probability being therapeutic target for treatment. In this study, the potential Rubicon blockage investigated. Lipid nanoparticles carrying Rubicon‐specific CRISPR‐Cas9 components exhibited accumulation, cell internalization, knockdown. A single administration results attenuated lipid deposition steatosis, lower circulating levels decreased adipocyte size mice. Furthermore, increase phosphatidylcholine phosphatidylethanolamine can be observed livers after silencing, along regulatory effects on metabolism‐related genes such as CD36, Gpcpd1, Chka, Lpin2. The indicate that knockdown improves glycerophospholipid metabolism thereby ameliorates progression, which provides strategy therapy via restoration Rubicon.

Language: Английский

---

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Life, Journal Year: 2024, Volume and Issue: 14(7), P. 844 - 844

Published: July 3, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading increased patient various complications. Recent research has been focused on new therapeutic strategies reduce the incidence and provide effective treatment plans prevent further irreversible damage. approach is multifactorial, primary focus weight loss management comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing exploring pharmacological therapies that could enhance MASLD.

Language: Английский

---